tiprankstipranks
Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Eiger Biopharmaceuticals (EIGR), Homology Medicines (FIXX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eiger Biopharmaceuticals (EIGRResearch Report) and Homology Medicines (FIXXResearch Report) with bullish sentiments.

Eiger Biopharmaceuticals (EIGR)

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Eiger Biopharmaceuticals yesterday and set a price target of $29.00. The company’s shares closed last Tuesday at $4.99.

According to TipRanks.com, Skorney has 0 stars on 0-5 stars ranking scale with an average return of -9.8% and a 38.3% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Enanta Pharmaceuticals, and Reneo Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eiger Biopharmaceuticals with a $38.33 average price target.

See the top stocks recommended by analysts >>

Homology Medicines (FIXX)

In a report issued on June 13, Jack Allen from Robert W. Baird maintained a Buy rating on Homology Medicines, with a price target of $10.00. The company’s shares closed last Tuesday at $1.87, close to its 52-week low of $1.30.

According to TipRanks.com, Allen is ranked 0 out of 5 stars with an average return of -34.2% and a 15.6% success rate. Allen covers the Healthcare sector, focusing on stocks such as Taysha Gene Therapies, Intellia Therapeutics, and Allogene Therapeutics.

Homology Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $8.02, implying a 307.1% upside from current levels. In a report issued on June 13, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EIGR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed